In the BioHarmony Drug Report Database

"Preview" Icon

Netarsudil

Rhopressa, Rhokiinsa (netarsudil) is a small molecule pharmaceutical. Netarsudil was first approved as Rhopressa on 2017-12-18. It is used to treat ocular hypertension and open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension and open-angle glaucoma. It is known to target rho-associated protein kinase 1 and rho-associated protein kinase 2. Rhopressa’s patents are valid until 2034-03-14 (FDA).

 

Trade Name

 

Rhokiinsa
 

Common Name

 

netarsudil
 

ChEMBL ID

 

CHEMBL4594250
 

Indication

 

ocular hypertension, open-angle glaucoma
 

Drug Class

 

Vasodilators: Rho protein kinase (ROCK) inhibitors

Image (chem structure or protein)

Netarsudil structure rendering